Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that mogamulizumab-associated rashes and alopecia are common in patients treated for mycosis fungoides and Sézary syndrome and may be linked with a good treatment response.

COVID-19 can cause different skin issues, including rashes and hair loss.

This review summarizes adverse events associated with EGFR-targeting cancer therapies, such as skin rashes and lung disease, and reports no new clinical results.

This review discusses the cutaneous side effects of targeted anticancer therapies, such as rashes and hair changes, but presents no new clinical results.

In this case report, mogamulizumab treatment for Sézary syndrome was associated with rashes and alopecia in a patient, highlighting the potential for immune-mediated side effects and suggesting that such adverse effects might indicate a favorable prognosis, though further studies are needed.

This case series observed the diagnostic challenges of secondary syphilis, highlighting diverse presentations such as rashes and systemic symptoms that can mimic other conditions, underscoring the importance of dermatological review, serological testing, and interdisciplinary care for effective treatment and management.

In this review, researchers highlighted that COVID-19 can cause various skin manifestations like maculopapular rashes and "COVID toes," which often precede or appear without respiratory symptoms, suggesting their potential for early detection and prognostic evaluation, especially in severe cases.

This study highlights that the skin can serve as a marker for systemic health during COVID-19 by showing symptoms like rashes and pigmentary changes, while also emphasizing dermatologists' key role in diagnosing COVID-induced and vaccine-related skin issues to enhance patient care and address vaccine hesitancy.

This article reviews how to properly take a dermatological history and conduct physical examinations for skin rashes and malignancies, discussing commonly used diagnostic tools and the Dermatology Life Quality Index system.

This study reported that immunotherapy in cancer patients can lead to skin-related immune adverse events, such as rashes, pruritus, and vitiligo, affecting a substantial proportion of patients.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This case report describes a woman in her 30s diagnosed with systemic lupus erythematosus, characterized by alopecia, arthritis, photosensitivity, and skin rashes, confirmed through positive serology.

This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.

This study found that 9.1% of surveyed previously-infected adult residents in Saudi Arabia reported skin symptoms related to COVID-19, with rashes being the most common.

The researchers reported that different allergens showed unique patterns based on season, gender, and age among patients with allergic skin rashes, with notable differences in allergen predispositions across groups.

This review discusses biotinidase deficiency, noting that biotin treatment from birth can prevent symptoms, but acknowledges the complexity and need for further understanding due to late-onset cases with varied clinical findings.

This review examined dermatologic symptoms associated with COVID-19 in 2,560 patients, with chilblains/pernio-like lesions being the most common, suggesting these symptoms may aid in early identification of cases.

This review discusses common skin conditions in primary care settings and provides guidance on differential diagnoses and selecting appropriate topical treatments, but it reports no new clinical results.

This review discusses common skin toxicities from cancer treatments and offers management strategies, particularly for regions like Australia and New Zealand with high UV exposure.

This article discusses suspected skin toxicity from drugs used to treat rheumatoid arthritis but reports no new clinical findings.

Nanoparticles could make hair dyes safer by reducing harmful effects.

In this study, an 11-year-old girl with acrodermatitis enteropathica showed significant improvement in symptoms after oral zinc therapy.

This review examines the increase in dermatologic conditions related to COVID-19, highlighting direct viral effects, PPE-related issues, and stress-related exacerbations, but reports no new clinical findings.

This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.

Hinokitiol and pantothenylethylether in hair products can cause strong allergic reactions.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.